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Autosomal dominant North Carolina macular dystrophy (NCMD) was first reported as a nosological entity more than 25 years ago.'
Particularly in the early stages of the disease, the variable but highly penetrant NCMD phenotype shows striking similarities to age related macular degeneration (AMD), a complex macular disorder with a high prevalence in western countries. As in AMD, small, yellowish drusen may be present in NCMD mainly in the central retina. At this stage, visual acuity is normal or slightly subnormal. In grade 2 NCMD the drusen appear "confluent" and may be accompanied by disciform lesions or the formation of subretinal choroidal neovascular membranes. In these cases visual acuity may be impaired. Severe cases of NCMD present with macular colobomas. In general, the disease onset is during infancy and appears to be non-progressive with a median visual acuity between 20/40 and 20/60.2 Electroretinography (ERG), electro-oculography (EOG), and colour vision are generally normal.
The variable expressivity of the disease gene was further highlighted by recent findings that showed NCMD and a clinically distinct phenotype referred to as central areolar pigment epithelial dystrophy (CAPED)3 4 to occur in separate but genealogically related branches of a single large North Carolina family. 5 This has led to the conclusion that the two disorders represent a single nosological entity and, therefore, have to be considered allelic.
In an effort to identify the NCMD gene by its chromosomal position, the disease locus, MCDR1, was mapped to chromosome 6q14-qi6.2 by genetic linkage analysis in a large North Carolina pedigree. 2 Subsequently, additional NCMD families ofvarious ethnic origins and from different geographical regions were identified and have mapped the MCDR1 locus to an approximately 7.2 cM interval flanked by DNA markers at D6S424 and D6S1671.6 So far, there is no clear indication for locus heterogeneity,' with the possible exception of one family of Indian origin where affected subjects present with features simulating NCMD.' Genetic linkage of the disease phenotype in this family to the MCDR1 locus was excluded. Recently, progressive bifocal chorioretinal atrophy (PBCRA) was mapped to an interval overlapping the MCDR1 locus.9 The possibility that NCMD and PBCRA are allelic disorders has been discussed, although clarification will have to await the isolation of the MCDR1 gene.
To facilitate the application of positional cloning strategies, alternate approaches are needed to refine the MCDR1 locus. Allelic association studies in combination with disease associated haplotype analyses have previously been used successfully to narrow the location of several important disease genes further.'0-12 In these studies an increased measure of 6.6 cM was shared between families L and A whereas families A and W had the disease haplotype 2-5-2 (at loci D6S249, D6S1716, and D6S1717) in common (fig 2, table 3 ). Assuming linkage equilibrium and using the allele frequencies as given in table 2 the probability of observing haplotype 5-2-10-4 in the general population is 0.230 x 0.292 x 0.001 x 0.230=1.5 x 10-4. Similarly, the probability of the disease haplotype 2-5-2 in the normal population is 4.6 x 10-2. Using the Bayesian theorem 1/(ab+a+b+1) (see Methods) the probability that the three families share the overlapping haplotype 5-2 at loci D6S 1716-D6S1717 by descent is 0.955.
Discussion
While meiotic mapping is a common approach to refining a disease locus the analysis of individual recombination events may in some instances lead to ambiguous interpretations. One source of error may stem from misdiagnosis of a crucial family member. Moreover, the simplest interpretation of the data generated usually includes the assumption of single recombination events. However, more complex rearrangements such as double recombinations or gene conversion events may occur and consequently give rise to incorrect conclusions. In addition, a specific genetic disease may be rare in a given population and the number of informative meioses in affected subjects may be limited as may be the informativeness of tightly linked DNA markers in a recombinant subject. In these cases the genetic mapping of a disease locus often does not give the necessary accuracy required for positional cloning approaches. It is, therefore, desirable to have a robust and independent source of information to narrow the location of a specific disease gene.
The analysis of allelic or haplotype association is based on population rather than individual studies.'7 Its principle and great potential for human genetics was first indicated in the context of sickle cell anaemia. 8 The simple strategy includes the comparison of allele frequencies in a random group of affected subjects with those of a normal control population. Both the lack of genetic heterogeneity and a low new mutation rate is bound to increase the power of detection of allelic/haplotype associations and has allowed this approach to be applied successfully to refine the location of many important disease genes, such as cystic fibrosis,"' Huntington's disease," or myotonic dystrophy.'2 In principle, one can assume an inverse correlation between the time of the mutational event and the extent of the physical region that is conserved around the disease gene. The more recent the origin of a mutation the larger the chromosomal region associated with the defective gene. Thus, the detection of non-random allelic association is bound to provide a high resolution approach for the precise mapping of a disease locus.
North Carolina macular dystrophy was originally desribed in a single large North American family that could be traced back to a founder from Ireland.' Since then, additional families from various ethnic and geographical regions have been identified including those from England, France, Spain, Belize, and Mexico.6 7 In addition, extensive genealogical studies showed that central areolar pigment epithelial dystrophy (CAPED), originally believed to be a distinct disease entity, in fact occurred in separate branches of the North American NCMD family. Thus, today, the two disorders are considered a single disease entity with highly variable expressivity.5 So far, NCMD has not been reported to occur in people of German descent. Moreover, although an earlier report described a three generation family of German origin segregating the CAPED phenotype,'3 the chromosomal location of the underlying gene defect and its relationship to NCMD still remains unclear. Our results now show that NCMD in the two German pedigrees is significantly linked to the known MCDR1 locus on chromosome 6q14-16.2 lending further support for the genetic homogeneity of this condition. Similarly, the German CAPED family also shows linkage to the MCDR1 locus confirming previous findings of allelism of these two conditions.'
As NCMD is an extremely rare disorder in Germany, we reasoned that the three German families may descend from a single ancestral founder. Indeed, genotyping identified an allele at locus D6S475 which is rare in the general population but segregating with the disease in two of our three NCMD families. Moreover, extended analyses identified excess allele and haplotype sharing between NCMD and additional marker loci tightly linked to D6S475. Accordingly, the NCMD haplotype 2-5-2-10-4 (D6S249 -D6S1716 -D6S1717 -D6S475 -D6S 1543) segregating in family A was shared at loci D6S1716, D6S1717, D6S475, and D6S1543 with affected subjects in family L. The shared haplotype extends over at least 6.6 cM suggesting a more recent link between the two NCMD families. In contrast, the affected chromosomes of family W shared alleles 2- represents the core haplotype probably harbouring the MCDR1 locus, thus narrowing the critical region to a 4.0 cM interval flanked by D6S249 and D6S475 (fig 2) . It is noted that additional highly polymorphic marker loci within or close to this interval are required and should be analysed to delineate further the chromosomal region of the core haplotype. Nevertheless, our approach shows the potential for the refinement of a disease locus by analysing small families that share a rare disease phenotype.
